A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose, 2 Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of Pf 06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects

Trial Profile

A Phase 1, Randomized, Double Blind, Placebo Controlled, Multiple Dose, 2 Way Crossover Study To Evaluate The Safety And Pharmacodynamic Effects Of Pf 06282999 Using An Endotoxin (Lipopolysaccharide) Induced Inflammatory Response Model In Healthy Adult Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2016

At a glance

  • Drugs PF 6282999 (Primary)
  • Indications Acute coronary syndromes
  • Focus Pharmacodynamics
  • Acronyms POM
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Mar 2015 Status changed from suspended to discontinued as reported by ClinicalTrials.gov record.
    • 22 Mar 2015 Planned End Date changed from 1 Sep 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
    • 22 Mar 2015 Planned primary completion date changed from 1 Sep 2015 to 1 Apr 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top